For research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
Mature Connecting Peptide (C-Peptide) is a 31 amino acid peptide that is a product from the proteolytic processing of proinsulin. In mouse and rat, contrary to humans, two isoforms of C-Peptide are present (isoforms 1 and 2). Through its G-protein coupled membrane receptor, C-Peptide activates Ca2+-dependent intracellular signaling pathways, resulting in subsequent activation of both Na+/K+ ATPase and endothelial nitric oxide synthase. C-Peptide and insulin are co-secreted in equimolar amounts in the bloodstream by pancreatic beta cells of the islets of Langerhans. However, C-Peptide has a longer half-life than insulin in serum, making it a good indicator of endogenous insulin production. A lack of endogenous C-Peptide contributes to development of long-term microvascular complications in the nerves, the kidneys, and the retina in Type 1 diabetes patients. C-Peptide has been considered as a possible therapy to prevent long-term complications of diabetes.
AlphaLISA technology allows the detection of molecules of interest in a no-wash, highly sensitive, quantitative assay. In an AlphaLISA assay, a biotinylated anti-analyte antibody binds to the Streptavidin-coated Donor beads while another anti-analyte antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads causes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.
|Assay Target Class||Peptide|
|Experimental Type||In vitro|
|Product Brand Name||AlphaLISA|
|Shipping Condition||Blue Ice|
|Unit Size||500 assay points|
The introduction of enzyme-linked immunosorbent assays (ELISAs) in the early 1970’s offered researchers a non-radiometric immunoassay platform without compromising sensitivity. Over the last 50 years scientists have made huge strides in disease research and drug discovery and a demand for greater assay throughput and sensitivity has evolved. In response, more robust immunoassays have been developed to address some of the limitations of the standard, colorimetric ELISA.
Find out about the most common limitations of traditional ELISAs and how different ELISA alternative technologies address these limitations.
The AlphaLISA® assay is a homogeneous immunoassay alternative to classical ELISA. AlphaLISA assays were originally utilized to detect analytesin cell cultures upernatants or serum/plasma samples.